Second-Line Treatment of HER2+ mBC and Recent Data Updates

Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).

Related Videos
Lisa A. Carey MD, ScM, FASCO
Expert on urothelial carcinoma
Experts on urothelial carcinoma
Susan Domchek, MD, FASCO
Expert on CSCC
Expert on CSCC
Experts on BTC
Experts on BTC
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Expert on AML
Related Content